BSGM - バイオシグ・テクノロジ―ズ （BioSig Technologies Inc.） バイオシグ・テクノロジ―ズBSGMのチャート
BSGMの企業情報
| symbol | BSGM |
|---|---|
| 会社名 | BioSig Technologies Inc （バイオシグ・テクノロジ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Electromedical_Electrotherapeutic Apparatus |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 BioSig Technologies Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company's PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms and helps in making clinical decisions in real-time. It is also developing signal-processing tools which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System. バイオシグ・テクノロジ―ズは米国の医療機器開発企業。生理学的信号から生物医学的信号の情報を抽出するための信号処理技術プラットフォ―ムの開発に従事。電気生理学研究やカテ―テル・アブレ―ション手術の現場で、すばやく正確な臨床判断を下す事を容易にするために開発された「PURE EP」システムが主力製品。本社所在地はカリフォルニア州ロサンゼルス。 biosig technologies, inc. (otcqb: bsgm) is a medical device company that is developing a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (ep) marketplace. led by a proven management team and a veteran, independent board of directors, minneapolis-based biosig is preparing to commercialize its pure ep system. |
| 本社所在地 | 12424 Wilshire Blvd. Suite 745 Los Angeles CA 90025 USA |
| 代表者氏名 | Kenneth L. Londoner ケネス・L・ロンドン |
| 代表者役職名 | Executive Chairman of the Board Chief Executive Officer |
| 電話番号 | +1 310-820-8100 |
| 設立年月日 | 39845 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.biosigtech.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bsgm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -15.38155 |
| 終値（lastsale） | 5.27 |
| 時価総額（marketcap） | 78723033.39 |
| 時価総額 | 時価総額（百万ドル） 77.82676 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 74.72862 |
| 当期純利益 | 当期純利益（百万ドル） -15.40750 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 BioSig Technologies Inc revenues was not reported. Net loss applicable to common stockholders increased 41% to $9M. Higher net loss reflects General and administrative increase of 88% to $6.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.67 to -$0.68. |
BSGMのテクニカル分析
BSGMのニュース
BioSig Technologies: New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market 2023/05/25 13:14:00 Finanz Nachrichten
WESTPORT, CT / ACCESSWIRE / May 25, 2023 / Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies'' (NASDAQ:BSGM) proprietary PURE EP Platform at the annual…
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market 2023/05/25 13:00:00 Accesswire
WESTPORT, CT / ACCESSWIRE / May 25, 2023 / Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies'' (NASDAQ:BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in New Orleans, LA, last week. The platform''s precision signal-capturing technology is meant to improve the speed, accuracy and precision of cardiac ablation, a widely-used surgery to treat atrial fibrillation. All three studies showed significant improvements over the conventional methods used for the procedure, putting BioSig on track for a successful commercial launch of the platform in a global cardiac ablation market projected to exceed $14 billion by 2032. 75,000 Ablation Procedures Are Performed Every Year In The U.S. According to the Centers for Disease Control (CDC), approximately 12.1 million Americans will have atrial fibrillation (AF) by 2030. AF is responsible for over 750,000 hospitalizations in the United States every year, according to the National Institutes of Health.
BioSig to Highlight New Data from the PURE EP Platform at Heart Rhythm 2023 2023/05/03 13:00:00 Wallstreet:Online
Leading physicians from Cleveland Clinic to present data from three posters that showcase the Company’s novel PURE EP Platform Westport, CT, May 03, 2023 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that
WKHS, OPEN and BILI are among pre market gainers 2023/03/23 13:00:16 Seeking Alpha
Advent Technologies Holdings (ADN) +34% enter into joint development pact.ZyVersa Therapeutics (ZVSA) +26%. BioSig Technologies (BSGM) +17%
BioSig Technologies Inc. (NASDAQ:BSGM) -8.70% Down Over Last Week, What Happens Next? 2023/03/11 16:00:00 Marketing Sentinel
In last trading session, BioSig Technologies Inc. (NASDAQ:BSGM) saw 0.38 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $1.05 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $51.04M. That closing price of BSGM’s stock is … BioSig Technologies Inc. (NASDAQ:BSGM) -8.70% Down Over Last Week, What Happens Next? Read More »
BioSig''s Signal Processing System for Arrhythmia Care To Be Featured At The Kansas City Heart Rhythm Symposium 2021/08/19 15:00:00 Benzinga
Westport, CT, Aug. 19, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM ) ("BioSig" or the "Company"), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would participate in the Kansas City Heart Rhythm Symposium, due to take place on August 21-22, 2021 at the Overland Park Convention Center. The Company''s clinical and commercial teams will host product demonstrations that will showcase the latest clinical data and the newest software features of its PURE EP(tm) System, the non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology. The Company''s technology will also be featured in a presentation at the Technology Theater during the Symposium. The presentation titled "PURE EP(tm) - A New Standard in Signal Processing" will be conducted during the sessions beginning at noon on Saturday, August 21, 2021, at the Technology Theatre.
BioSig to Host Conference Call to Unblind Clinical Data Collected with its Signal Processing Technology for Arrhythmia Care 2021/07/12 14:30:00 Intrado Digital Media
Westport, CT, July 12, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a call to discuss the recent conclusions of its PURE EP(tm) 2.0 study, which enrolled 51 patients at Texas Cardiac Arrhythmia Institute at St. Davids Medical Center in Austin, TX, Mayo Clinic Florida Campus in Jacksonville, FL and Massachusetts General Hospital in Boston, MA.
BioSig Announces Closing of Public Offering of Common Stock 2021/07/07 20:10:00 Intrado Digital Media
Westport, CT, July 07, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the completion of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering were $10 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig.
Mayo Clinic Purchases BioSig''s PURE EP for use at its Phoenix Location 2021/07/06 13:44:12 Benzinga
According to a recently filed 8-k, BioSig Technologies, Inc. (NASDAQ: BSGM ) received a new purchase order from the Mayo Foundation for medical education and research. The institution commenced the evaluation of the PURE EP System in April 2021. Under the terms of the commercial transaction, the Foundation is acquiring the PURE EP System for clinical use at Mayo Clinic Phoenix Campus in Arizona. Previously, the institution acquired multiple PURE EP Systems for its Florida and Minnesota Mayo Clinic campuses. To date, more than 1,000 patient cases have been conducted using the PURE EP System by 52 physicians across nine clinical sites. The company is excited about the new sale to the Mayo Clinic and is confident that this denotes the efficacy and potential of its technologies. In fact, its not just the Mayo Clinic Full story available on Benzinga.com
BioSig Announces Closing of Public Offering of Common Stock 2021/07/07 20:10:00 Intrado Digital Media
Westport, CT, July 07, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the completion of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering were $10 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig.
Mayo Clinic Purchases BioSig''s PURE EP for use at its Phoenix Location 2021/07/06 13:44:12 Benzinga
According to a recently filed 8-k, BioSig Technologies, Inc. (NASDAQ: BSGM ) received a new purchase order from the Mayo Foundation for medical education and research. The institution commenced the evaluation of the PURE EP System in April 2021. Under the terms of the commercial transaction, the Foundation is acquiring the PURE EP System for clinical use at Mayo Clinic Phoenix Campus in Arizona. Previously, the institution acquired multiple PURE EP Systems for its Florida and Minnesota Mayo Clinic campuses. To date, more than 1,000 patient cases have been conducted using the PURE EP System by 52 physicians across nine clinical sites. The company is excited about the new sale to the Mayo Clinic and is confident that this denotes the efficacy and potential of its technologies. In fact, its not just the Mayo Clinic Full story available on Benzinga.com
Financings for July 2, 2021 2021/07/02 16:00:00 BioWorld
Med-tech firms raising money in public or private financings, including: Biosig Technologies, Nyxoah.
BioSig Technologies Raises $10M Via Equity Issued At $4/Share 2021/07/02 13:37:27 Benzinga
BioSig Technologies Inc (NASDAQ: BSGM ) has priced its previously announced underwritten public offering of 2.5 million shares at $4.00 per share , representing a discount of 8% from the last close price of $4.35 on Thursday. The gross proceeds will be approximately Full story available on Benzinga.com
BioSig Announces Pricing of Public Offering of Common Stock 2021/07/02 12:15:00 Intrado Digital Media
Westport, CT, July 02, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (BioSig or the Company), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced pricing of its previously announced underwritten public offering of 2,500,000 shares of its common stock, $0.001 par value per share, at a price to the public of $4.00 per share. The gross proceeds to BioSig from this offering are expected to be approximately $10 million, or approximately $11.5 million if the underwriter exercises its 30-day option to purchase an additional 15% of the number of shares of common stock offered in the public offering in full, before deducting the underwriting discounts and commissions and estimated offering expenses payable by BioSig. The offering is expected to close on July 7, 2021, subject to the satisfaction of customary closing conditions.